|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shaukat A, Mongin SJ, Geisser MS, Lederle
FA, Bond JH, Mandel JS and Church TR: Long-term mortality after
screening for colorectal cancer. N Engl J Med. 369:1106–1114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schrag D, Weiser MR, Goodman KA, Gonen M,
Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem
JG, et al: Neoadjuvant chemotherapy without routine use of
radiation therapy for patients with locally advanced rectal cancer:
A pilot trial. J Clin Oncol. 32:513–518. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosset JF, Calais G, Mineur L, Maingon P,
Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC,
Bolla M, et al: Fluorouracil-based adjuvant chemotherapy after
preoperative chemoradiotherapy in rectal cancer: Long-term results
of the EORTC 22921 randomised study. Lancet Oncol. 15:184–190.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cecchin E, D'Andrea M, Lonardi S, Zanusso
C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F and
Toffoli G: A prospective validation pharmacogenomic study in the
adjuvant setting of colorectal cancer patients treated with the
5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Pharmacogenomics J. 13:403–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tong M, Zheng W, Lu X, Ao L, Li X, Guan Q,
Cai H, Li M, Yan H, Guo Y, et al: Identifying clinically relevant
drug resistance genes in drug-induced resistant cancer cell lines
and post-chemotherapy tissues. Oncotarget. 6:41216–41227. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL,
Wu H, Patel R, Liu D, Qin ZH, Shih IM and Yang JM: NAC1 modulates
sensitivity of ovarian cancer cells to cisplatin by altering the
HMGB1-mediated autophagic response. Oncogene. 31:1055–1064. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsunoda K, Oikawa H, Tada H, Tatemichi Y,
Muraoka S, Miura S, Shibazaki M, Maeda F, Takahashi K, Akasaka T,
et al: Nucleus accumbens-associated 1 contributes to cortactin
deacetylation and augments the migration of melanoma cells. J
Invest Dermatol. 131:1710–1719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Y, Cheng Y, Ren X, Hori T,
Huber-Keener KJ, Zhang L, Yap KL, Liu D, Shantz L, Qin ZH, et al:
Dysfunction of nucleus accumbens-1 activates cellular senescence
and inhibits tumor cell proliferation and oncogenesis. Cancer Res.
72:4262–4275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jinawath N, Vasoontara C, Yap KL,
Thiaville MM, Nakayama K, Wang TL and Shih IM: NAC-1, a potential
stem cell pluripotency factor, contributes to paclitaxel resistance
in ovarian cancer through inactivating Gadd45 pathway. Oncogene.
28:1941–1948. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakayama K, Nakayama N, Davidson B, Sheu
JJ, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman
RJ, et al: A BTB/POZ protein, NAC-1, is related to tumor recurrence
and is essential for tumor growth and survival. Proc Natl Acad Sci
USA. 103:18739–18744. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davidson B, Berner A, Trope' CG, Wang TL
and Shih IeM: Expression and clinical role of the bric-a-brac
tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian
carcinoma effusions. Hum Pathol. 38:1030–1036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Yang JW, Ren X and Yang JM: NAC1
and HMGB1 enter a partnership for manipulating autophagy.
Autophagy. 7:1557–1558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okazaki K, Nakayama N, Nariai Y, Nakayama
K, Miyazaki K, Maruyama R, Kato H, Kosugi S, Urano T and Sakashita
G: Nuclear localization signal in a cancer-related transcriptional
regulator protein NAC1. Carcinogenesis. 33:1854–1862. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao M, Wu RC, Herlinger AL, Yap K, Kim JW,
Wang TL and Shih IeM: Identification of the NAC1-regulated genes in
ovarian cancer. Am J Pathol. 184:133–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu PH, Hung SH, Ren T, Shih IeM and Tseng
Y: Cell cycle-dependent alteration in NAC1 nuclear body dynamics
and morphology. Phys Biol. 8:0150052011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Larochelle A, Choi U, Shou Y, Naumann N,
Loktionova NA, Clevenger JR, Krouse A, Metzger M, Donahue RE, Kang
E, et al: In vivo selection of hematopoietic progenitor cells and
temozolomide dose intensification in rhesus macaques through
lentiviral transduction with a drug resistance gene. J Clin Invest.
119:1952–1963. 2009.PubMed/NCBI
|
|
19
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hayashida T, Takahashi F, Chiba N,
Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco Md,
Wijendran V, Shioda T, et al: HOXB9, a gene overexpressed in breast
cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad
Sci USA. 107:1100–1105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Iwasaki M, Ficara F, Lin C,
Matheny C, Wong SH, Smith KS and Cleary ML: GSK-3 promotes
conditional association of CREB and its coactivators with MEIS1 to
facilitate HOX-mediated transcription and oncogenesis. Cancer Cell.
17:597–608. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aberdam D, Negreanu V, Sachs L and Blatt
C: The oncogenic potential of an activated Hox-2.4 homeobox gene in
mouse fibroblasts. Mol Cell Biol. 11:554–557. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng W, Liu J, Yoshida H, Rosen D and
Naora H: Lineage infidelity of epithelial ovarian cancers is
controlled by HOX genes that specify regional identity in the
reproductive tract. Nat Med. 11:531–537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ko SY, Barengo N, Ladanyi A, Lee JS,
Marini F, Lengyel E and Naora H: HOXA9 promotes ovarian cancer
growth by stimulating cancer-associated fibroblasts. J Clin Invest.
122:3603–3617. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferrarese R, Harsh GR VI, Yadav AK, Bug E,
Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP,
Dai F, et al: Lineage-specific splicing of a brain-enriched
alternative exon promotes glioblastoma progression. J Clin Invest.
124:2861–2876. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou J, Zhan S, Tan W, Cheng R, Gong H and
Zhu Q: P300 binds to and acetylates MTA2 to promote colorectal
cancer cells growth. Biochem Biophys Res Commun. 444:387–390. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Azmi AS, Bao B and Sarkar FH: Exosomes in
cancer development, metastasis, and drug resistance: A
comprehensive review. Cancer Metastasis Rev. 32:623–642. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Medina-Ramirez CM, Goswami S, Smirnova T,
Bamira D, Benson B, Ferrick N, Segall J, Pollard JW and Kitsis RN:
Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis,
and chemoresistance. Cancer Res. 71:7705–7715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei Y, Zou Z, Becker N, Anderson M,
Sumpter R, Xiao G, Kinch L, Koduru P, Christudass CS, Veltri RW, et
al: EGFR-mediated Beclin 1 phosphorylation in autophagy
suppression, tumor progression, and tumor chemoresistance. Cell.
154:1269–1284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang WJ, Song MJ, Park EY, Lee JJ, Park
JH, Park K, Park JH and Kim HP: Transcription factors Sp1 and Sp3
regulate expression of human ABCG2 gene and chemoresistance
phenotype. Mol Cells. 36:368–375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Breau MA, Wilkinson DG and Xu Q: A Hox
gene controls lateral line cell migration by regulating chemokine
receptor expression downstream of Wnt signaling. Proc Natl Acad Sci
USA. 110:16892–16897. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gaspar N, Marshall L, Perryman L, Bax DA,
Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis
RM, et al: MGMT-independent temozolomide resistance in pediatric
glioblastoma cells associated with a PI3-kinase-mediated HOX/stem
cell gene signature. Cancer Res. 70:9243–9252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brumatti G, Salmanidis M, Kok CH, Bilardi
RA, Sandow JJ, Silke N, Mason K, Visser J, Jabbour AM, Glaser SP,
et al: HoxA9 regulated Bcl-2 expression mediates survival of
myeloid progenitors and the severity of HoxA9-dependent leukemia.
Oncotarget. 4:1933–1947. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alharbi RA, Pettengell R, Pandha HS and
Morgan R: The role of HOX genes in normal hematopoiesis and acute
leukemia. Leukemia. 27:1000–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Johansson AC, Ansell A, Jerhammar F, Lindh
MB, Grénman R, Munck-Wikland E, Östman A and Roberg K:
Cancer-associated fibroblasts induce matrix
metalloproteinase-mediated cetuximab resistance in head and neck
squamous cell carcinoma cells. Mol Cancer Res. 10:1158–1168. 2012.
View Article : Google Scholar : PubMed/NCBI
|
